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Abstract
Introduction: Bipolar disorder (BD) is a prevalent, chronic and progressive illness. There is a growing 
body of evidence indicating that brain-derived neurotrophic factor (BDNF) plays an important 
role in the pathophysiology of BD. Objective: The aim of this study was to evaluate BDNF plasma 
levels in BD patients with long term illness in comparison with controls. Methods: 87 BD type I 
patients and 58 controls matched by age, gender and education level were enrolled in this study. 
All subjects were assessed by the Mini-International Neuropsychiatric Interview and the patients 
by the Young Mania Rating Scale and the Hamilton Depression Rating Scale. The plasma levels 
of BDNF were measured by ELISA. Results: On average, patients had suffered from BD for 23.4 
years. In comparison with controls, BD patients with mania presented a 1.90-fold increase in 
BDNF plasma levels (p = .001), while BD patients in remission presented a 1.64-fold increase 
LQ%'1)SODVPDOHYHOVS %'1)SODVPDOHYHOVZHUHQRWLQÁXHQFHGE\DJHOHQJWKRILOOQHVV
or current medications. Conclusions: The present study suggests that long-term BD patients 
exhibit increased circulating levels of BDNF.
© 2013 Associação Brasileira de Psiquiatria.Published by Elsevier Editora Ltda. 
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Introduction
Bipolar disorder (BD) is a prevalent, severe and chronic disorder 
that affects mood and cognitive functions. In contrast to the old 
Kraepelin concept that BD has a cyclic and permanent course,1 
recent evidence has shown an accelerated and progressive 
course.2 The physiopathology of BD is unknown, but a body of 
evidence suggests a complex interaction among susceptibility 
genes, environmental stressors and biochemical mechanisms.3 
The modulation of brain-derived neurotrophic factor (BDNF) 
levels has been suggested to be one of the major mechanisms 
involved in BD physiopathology. However, there is scarce infor-
mation regarding the circulating levels of BDNF in long-term BD 
patients. Accordingly, the main aim of the present study was to 
evaluate plasma levels of BDNF in a sample of long-term BD pa-
tients in comparison with matched healthy subjects. Secondary 
analyses were performed to identify clinical and demographic 
factors associated with the variation in BDNF levels.
Methods
This was a cross-sectional study that evaluated 87 BD 
type I patients and 58 healthy controls matched by age and 
gender. Patients were consecutively recruited from out-
patient and inpatient psychiatric settings at the Instituto 
de Previdência dos Servidores do Estado de Minas Gerais 
(IPSEMG), Belo Horizonte, Brazil during a one-year-period. 
This clinic provides long term assistance for patients with 
chronic mental illnesses. All patients were medicated. The 
local institutional review board approved the study, which is 
in accordance with the Helsinki Declaration of 1975. All par-
ticipants were more than 18 years old. All volunteers provided 
their written consent after a complete explanation of the 
procedures involved in the research protocol was provided. 
Patients and healthy controls were assessed with the 
Mini-International Neuropsychiatric Interview (M.I.N.I.-Plus) 
WRFRQÀUP%'DQGRWKHUFRPRUELGSV\FKLDWULFGLVRUGHUVLQ
patients), or to exclude a history of psychiatric disorders 
(in controls).4 Patients with BD were also examined with the 
17-item version of the Hamilton Depression Rating Scale, 
(HDRS)5 and the Young Mania Rating Scale (YMRS)6 to char-
acterize the severity of depressive and manic symptoms, 
UHVSHFWLYHO\5HPLVVLRQZDVGHÀQHGDV+'56DQG<056VFRUHV
lower than seven points for at least eight consecutive weeks. 
Clinical assessment of patients included the collection of the 
following demographic and clinical variables: gender, age, 
years of education, length of disease, current medications 
and medical comorbidities. Length of illness was calculated 
E\VXEWUDFWLQJDJHDWÀUVWPDMRUGHSUHVVLYHRUPDQLFPRRG
episode, as recorded in the clinical record or reported by 
the subject or family members, from the subject's current 
age in years. The healthy control group was recruited from 
the local population and did not have any personal psychi-
atric disorder (evaluated through M.I.N.I.-Plus) or family 
history of psychiatry disorder, suicide attempts or completed 
suicide. Subjects with dementia, infectious or autoimmune 
GLVHDVHVRUZKRKDGXVHGVWHURLGVDQWLLQÁDPPDWRU\GUXJV
or antibiotics four weeks before venipuncture were excluded 
from the study. 
Ten milliliters of blood were drawn between 8 and 10 
a.m. from each subject by venipuncture into a sodium 
heparin tube, on the same day of the clinical assessment. 
The blood was immediately centrifuged at 3,000 g for 10 
min at 4°C, twice. The plasma was collected and stored at 
70°C until assayed.
Plasma levels of BDNF were measured by enzyme-linked 
immunosorbent assay (ELISA) according to the procedures 
supplied by the manufacturer (DuoSet, R&D Systems, 
Minneapolis, MN, USA). All samples were assayed in duplicate. 
Lower detection limits were reported by the manufacturer to 
be 5 pg/mL for BDNF. Concentrations are expressed as pg/mL.
Statistical analyses were performed using SPSS software 
version 17.0 (SPSS Inc., Chicago, IL, USA). Associations be-
tween dichotomous variables were assessed with a chi-square 
test. All variables were tested for normality of distribution 
by the Shapiro-Wilk test, which did not lead to rejection of 
normality for any data. Two groups (patients vs. controls 
or mania vs. remission) were compared by a Student t-test. 
Difference among groups was evaluated using analysis of vari-
ance (ANOVA) followed by the Dunn post-hoc test. Pearson's 
correlation analyses were performed to examine the rela-
tionship between plasma levels of BDNF and age, length of 
illness, and severity of manic and depressive symptoms. All 
statistical tests were two-tailed and were performed using 
DVLJQLÀFDQFHOHYHORIŞ 
Results
The mean age of BD patients and their mean years of formal 
education were 49.56 years and 10.08 years, respectively. 
The mean length of illness was 23.35 years. Fifty nine out of 
87 BD patients (67.8%) were female. The mean age of con-
trols and their years of formal education were 46.79 years 
and 10.16 years, respectively. Forty two out of 58 controls 
ZHUHIHPDOH7KHUHZHUHQRVLJQLÀFDQWGLIIHUHQFHV
between the BD group and the controls regarding age, gender 
and years of education. 
At the time of the interview, 48 patients were in mania 
and 39 patients in remission. BD patients in mania and in 
remission did not differ in many clinical variables, includ-
ing length of illness, current medications, and clinical 
and psychiatric co-morbidities. BD patients in mania pre-
sented higher YMRS scores in comparison with BD patients 
in remission (25.23 vs 1.12), p = .001). BD patients in mania 
also presented higher HDRS scores in comparison with BD 
patients in remission (5.25 vs. 2.23, p = .007).
BD patients presented a 1.78-fold increase in BDNF plasma 
levels compared with controls (p < .001). BD patients in ma-
nia presented a 1.90-fold increase in BDNF plasma levels in 
comparison with healthy controls (p = .001, Dunn’s post-hoc 
test). BD patients in remission presented a 1.64-fold increase 
in BDNF plasma levels in comparison with healthy controls 
(p = .03, Dunn’s post-hoc test). BD patients in mania tended 
to have higher plasma levels than BD patients in remission, 
EXW WKLV GLIIHUHQFH GLG QRW UHDFK VWDWLVWLFDO VLJQLÀFDQFH 
(p = .34). BDNF plasma levels of BD patients did not correlate 
with age (p = .63), length of illness (p = .67), or severity of 
manic (p = .23) or depressive (p = .82) symptoms. 
In BD patients, plasma levels of BDNF did not correlate 
with the presence of psychiatric and clinical co-morbidities, 
substance dependence, or the use of any mood stabilizing 
drug, i.e., atypical antipsychotics (p = .87), lithium (p = .13) 
or anticonvulsants (p = .82).
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Discussion
The present study reports the plasma BDNF levels of a large 
sample of patients with long-term BD. To date, few studies 
have assessed BD patients with long-term illness. BD patients 
demonstrated increased BDNF plasma levels in comparison 
with healthy controls, regardless of current mood state or 
medications.
A recent meta-analysis showed that BDNF levels decrease 
during mood states, and BDNF levels were negatively corre-
lated with the severity of mood symptoms.7 Moreover, BDNF 
levels were normal in patients in euthymia and negatively 
correlated with the length of BD.7 The results of the pres-
HQWZRUNFRQWUDGLFWWKHVHPHWDDQDO\WLFÀQGLQJV,WLVZRUWK
mentioning, however, that this meta-analysis did not include 
BD patients with more than 20 years of illness.
6LQFHFLUFXODWLQJOHYHOVRI%'1)PD\UHÁHFWLWVFHUHEUDO
concentration,8 it is possible that higher BDNF concentrations 
over the long course of BD may represent a reaction to cere-
bral damage that occurred in the early stage of the disease, 
when neurodegenerative or neuroprogressive mechanisms 
seem to be more intense and BDNF levels are decreased.9 
This assumption is in line with evidence from other neuro-
psychiatric disorders, such as long-term schizophrenia,10,11 
and an experimental model of Alzheimer’s disease.12 A second 
hypothesis relates the effect of mood stabilizing drugs to 
BDNF levels. For instance, lithium therapy seems to increase 
the levels of BDNF in BD patients in mania.13
This study has strengths and limitations that must be con-
sidered for the interpretation of the results. The diagnostic 
interviews of both patients and controls were performed 
using the same protocol, overcoming a limitation of previ-
ous similar studies. In addition, the large sample size and 
the exclusion of patients with other medical conditions, 
VXFKDVLQÁDPPDWRU\GLVHDVHVFDQEHFRQVLGHUHGVWUHQJWKV
of the study. The use of medications by all BD patients is a 
limitation.
In conclusion, our data reinforce the view that there is 
BDNF imbalance in long-term BD.
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